This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

Disclosed is a method for high-throughput screening of non-target biomarkers based on metabolic disturbance caused by pollutants, belonging to the field of environmental exposure and health. The method includes the following steps: (1) extracting to obtain extracts to be tested; (2) performing chromatographic analysis to obtain a spectrum containing chromatographic peaks; (3) identifying and labeling features of pollutants, taking chromatographic peaks other than the features of the pollutants as features of potential metabolites, and performing non-target labeling of the features of the potential metabolites; (4) establishing a linear regression model by taking the peak areas of the features of the potential metabolites as dependent variables and the peak areas of the features of the pollutants as independent variables; (5) operating the model, and performing non-target screening of the biomarkers to preliminarily obtain related biomarkers; (6) identifying the MS spectra and MS/MS spectra of the preliminarily obtained biomarkers, and identifying biomarkers related to pollutant exposure. The method of the present invention obviously improves the accuracy of biomarker screening, and improves the throughput of biomarker screening.

The invention relates to a method for identifying one or more polymorphisms in nucleic acid samples, comprising: (a) performing a reproducible complexity reduction on a plurality of nucleic acid samples to provide a plurality of libraries of the nucleic acid samples comprising amplified fragments, wherein the reproducible complexity reduction comprises amplifying fragments of the nucleic acid samples using one or more primers to obtain the amplified fragments, and wherein the amplified fragments in each library comprise a unique identifier sequence to indicate origin of each library obtained by the reproducible complexity reduction; (b) combining the plurality of libraries to obtain a combined library and sequencing at least a portion of the combined library to obtain sequences; (c) aligning the sequences to obtain an alignment; and (d) identifying one or more polymorphisms in the plurality of nucleic acid samples.

A cartridge for use in in-vitro diagnostics, the cartridge including a cartridge housing, a cartridge element, disposed within the cartridge housing and defining a plurality of operational volumes, at least some of the plurality of operational volumes being mutually linearly aligned, a fluid solution transporter operative to transfer fluid solutions from at least one of the plurality of operational volumes to at least another of the plurality of operational volumes, the fluid solution transporter including a linearly displaceable transport element operative to sequentially communicate with interiors of the at least some of the plurality of operational volumes and a venter, including a linearly displaceable venting element, operative in coordination with the fluid solution transporter to vent at least one of the plurality of operational volumes.

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-XR2, and wherein X is a mono- to multiatomic linker and where R.sup.1 and R.sup.2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I), which is: R1-XR2, in which either the moeities R1 or R2 or X carry a drug that is covalently attached to the diboron compound.

The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject or a live or a post-mortem animal using oral fluid collected from the post-mortem subject or live or post-mortem animal. The method comprises collecting a sample of oral fluid from a post-mortem subject or a live or a post-mortem animal, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal, and identifying the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject. Further, the qualitative and quantitative results are obtained in as little as three hours.

A method of analysing a sample mass spectrum comprises comparing a sample mass spectrum of a sample with each reference mass spectrum of plural reference mass spectra. A similarity index is assigned to each reference mass spectrum of the plural reference mass spectra based on similarity between the sample mass spectrum and the reference mass spectrum. For each group of one or more groups of the plural reference mass spectra, the similarity indexes for the reference mass spectra belonging to the group are combined so as to provide a group index for the group at a first level of a hierarchy of sample characteristics. The reference mass spectra belonging to each group are mass spectra of reference samples that have a particular characteristic in common. The method provides a way to categorise a sample as belonging to a particular group of reference samples.

A method of analysing a sample mass spectrum comprises comparing a sample mass spectrum of a sample with each reference mass spectrum of plural reference mass spectra. A similarity index is assigned to each reference mass spectrum of the plural reference mass spectra based on similarity between the sample mass spectrum and the reference mass spectrum. For each group of one or more groups of the plural reference mass spectra, the similarity indexes for the reference mass spectra belonging to the group are combined so as to provide a group index for the group at a first level of a hierarchy of sample characteristics. The reference mass spectra belonging to each group are mass spectra of reference samples that have a particular characteristic in common. The method provides a way to categorise a sample as belonging to a particular group of reference samples.

The invention relates to a method for identifying one or more polymorphisms in nucleic acid samples, comprising: (a) performing a reproducible complexity reduction on a plurality of nucleic acid samples to provide a plurality of libraries of the nucleic acid samples comprising amplified fragments, wherein the reproducible complexity reduction comprises amplifying fragments of the nucleic acid samples using one or more primers to obtain the amplified fragments, and wherein the amplified fragments in each library comprise a unique identifier sequence to indicate origin of each library obtained by the reproducible complexity reduction; (b) combining the plurality of libraries to obtain a combined library and sequencing at least a portion of the combined library to obtain sequences; (c) aligning the sequences to obtain an alignment; and (d) identifying one or more polymorphisms in the plurality of nucleic acid samples.

The invention relates to detection the presence of a target molecule in a sample, wherein the sample is contacted with a substrate, the substrate subsequently being washed in a wash step. In particular, the invention relates to a method of detecting the presence of a target molecule in a sample, the method comprising: (a) contacting the sample (37) with a substrate having immobilized thereon probe molecules that specifically binds to the target molecule; (b) washing the substrate (38) in a wash step by a wash fluid in order to remove or dilute unbound target molecules; (c) detect the presence of resultant binding complexes (39) on the substrate to determine whether the target molecule is present in the sampleThe wash fluid being substantially refractive index matched to the substrate.